Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone720-643-5200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.39 million
Profitability
Miscellaneous
Employees77
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable
Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions
What is Miragen Therapeutics' stock symbol?
Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."
How were Miragen Therapeutics' earnings last quarter?
Miragen Therapeutics Inc (NASDAQ:MGEN) released its quarterly earnings data on Wednesday, May, 8th. The medical research company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.03. The medical research company earned $0.37 million during the quarter, compared to analysts' expectations of $1.35 million. Miragen Therapeutics had a negative return on equity of 71.91% and a negative net margin of 998.26%. View Miragen Therapeutics' Earnings History.
When is Miragen Therapeutics' next earnings date?
What price target have analysts set for MGEN?
3 analysts have issued 12-month price objectives for Miragen Therapeutics' stock. Their forecasts range from $18.50 to $24.00. On average, they anticipate Miragen Therapeutics' share price to reach $21.25 in the next twelve months. This suggests a possible upside of 819.9% from the stock's current price. View Analyst Price Targets for Miragen Therapeutics.
What is the consensus analysts' recommendation for Miragen Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Miragen Therapeutics.
Has Miragen Therapeutics been receiving favorable news coverage?
News headlines about MGEN stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Miragen Therapeutics earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Miragen Therapeutics.
Who are some of Miragen Therapeutics' key competitors?
Some companies that are related to Miragen Therapeutics include Celcuity (CELC), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), Psychemedics (PMD), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), Cancer Genetics (CGIX), CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS), OpGen (OPGN) and Aeon Global Health (AGHC).
What other stocks do shareholders of Miragen Therapeutics own?
Who are Miragen Therapeutics' key executives?
Miragen Therapeutics' management team includes the folowing people:
- Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 55)
- Mr. Adam Scott Levy, Chief Bus. Officer (Age 41)
- Dr. Paul D. Rubin, Exec. VP of R&D (Age 65)
- Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
- Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 74)
Who are Miragen Therapeutics' major shareholders?
Miragen Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Motley Fool Asset Management LLC (0.56%). Company insiders that own Miragen Therapeutics stock include Adam Scott Levy, Bruce Booth and Thomas E Hughes. View Institutional Ownership Trends for Miragen Therapeutics.
Which major investors are buying Miragen Therapeutics stock?
MGEN stock was acquired by a variety of institutional investors in the last quarter, including Motley Fool Asset Management LLC. Company insiders that have bought Miragen Therapeutics stock in the last two years include Adam Scott Levy, Bruce Booth and Thomas E Hughes. View Insider Buying and Selling for Miragen Therapeutics.
How do I buy shares of Miragen Therapeutics?
Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Miragen Therapeutics' stock price today?
One share of MGEN stock can currently be purchased for approximately $2.31.
How big of a company is Miragen Therapeutics?
Miragen Therapeutics has a market capitalization of $71.45 million and generates $8.39 million in revenue each year. The medical research company earns $-32,700,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Miragen Therapeutics employs 77 workers across the globe.View Additional Information About Miragen Therapeutics.
What is Miragen Therapeutics' official website?
How can I contact Miragen Therapeutics?
Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]
MarketBeat Community Rating for Miragen Therapeutics (NASDAQ MGEN)
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
